Radiotherapy dosing in intracranial ependymoma using the national cancer database
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04805-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Melanie L Rose und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA. melanie.l.rose@hitchcock.org. Hauptthemen laut MEDLINE: Ependymoma, Brain Neoplasms, Databases, Factual. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE: To determine the dose-dependent effect of adjuvant radiotherapy on survival for pediatric intracranial ependymomas and explore patient and disease characteristics that experience survival benefit from higher doses. METHODS: Data was accessed from the National Cancer Database. Inclusion criteria was comprised of a diagnosis of non-metastatic intracranial ependymoma, World Health Organization (WHO) grade 2 or 3, surgical resection, adjuvant radiotherapy between 4500-6300 cGy, and non-missing survivorship data. Crude and adjusted Cox proportional hazard ratios (HRs) were calculated to estimate the associations of patient, tumor, and treatment characteristics with overall survival (OS). Kaplan-Meier (KM) estimations were used to visualize survival curves for dosing for the general cohort and by subgroups (age, resection extent, and grade). RESULTS: Of the 1154 patients who met inclusion criteria, 405 received ≤ 5400 cGy and 749 received > 5400 cGy. We found no difference in OS crude (0.95, 95% CI 0.72-1.06) or adjusted (0.88, 95% CI 0.46-1.69) HR for those receiving ≤ 5400 cGy. KM curves showed no difference in OS for dosing for the general cohort based on age, surgical extent, and grade. However, there was better OS in those with WHO grade 2 tumors compared to grade 3 regardless of dose received. CONCLUSIONS: There was no difference in OS between patients who received ≤ 5400 cGy compared to > 5400 cGy. We found improved OS in those with grade 2 tumors compared to grade 3, however there was no difference in OS based on dose received by tumor grade, age, or resection extent. Limitations in data available prevent exploring other outcomes or toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA. melanie.l.rose@hitchcock.org.
- The Dartmouth Institute, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA. melanie.l.rose@hitchcock.org.
- The Dartmouth Institute, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
- Department of Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
- Department of Radiation Oncology, Cancer Care Northwest, Spokane, WA, USA.
- Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
ORCID-Profile: Melanie L Rose
Förderung
- NCI NIH HHS
Zitieren
APA
Rose, M. L., Moen, E., Ager, B., Bajaj, B., Poppe, M., Russo, G., & Yock, T. I. (2024). Radiotherapy dosing in intracranial ependymoma using the national cancer database. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04805-0
Vancouver
Rose ML, Moen E, Ager B, Bajaj B, Poppe M, Russo G, et al. Radiotherapy dosing in intracranial ependymoma using the national cancer database. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04805-0
BibTeX
@article{Rose2024,
author = {Rose, Melanie L and Moen, Erika and Ager, Bryan and Bajaj, Benjamin and Poppe, Matthew and Russo, Gregory and Yock, Torunn I},
title = {Radiotherapy dosing in intracranial ependymoma using the national cancer database},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04805-0}
}
EUVIMED